Why Arrowhead Pharmaceuticals, Inc. (ARWR) stock moved
Arrowhead Pharmaceuticals, Inc. (ARWR) shares tumbled 11.9% to $71.06 as of September 15, 2026, a sharp decline from the prior close of $80.67. BestStocks flagged the session as a major change for ARWR. Below, we break down what changed for ARWR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ARWR fell 11.9% to $71.06
Arrowhead Pharmaceuticals declined 10.49% to $72.21 following profit-taking after recent clinical data announcements, according to market commentary. The company released interim topline data for ARO-DIMER-PA and positive Phase 3 SHASTA trial results showing major triglyceride reductions; the sell-the-news reaction reflects traders locking in gains after a multi-month rally. Volume was elevated at 2.51x the time-adjusted average (2.5M shares), consistent with the sharp intraday move. Arrowhead's earnings release scheduled for November 24, 2026 (consensus EPS estimate: −$1.52); monitor for updates on ARO-DIMER-PA regulatory timelines and cash position.
What it means for Arrowhead Pharmaceuticals, Inc. investors
For Arrowhead Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Arrowhead Pharmaceuticals, Inc. (ARWR) moved +4.01% from $71.65 to $74.52 on 2026-07-21; Arrowhead Pharmaceuticals, Inc. (ARWR) moved +4.09% from $71.38 to $74.30 on 2026-07-17. Weighing against that: Material negative event; Sharp 11.9% decline — elevated risk. Wall Street's consensus price target sits at $104.43, implying +47.0% upside from $71.06. BestStocks rates the overall signal quality medium (64/100). With earnings roughly 70 days out, the next report is the most likely near-term test of the move.
ARWR price reaction
ARWR last traded at $71.06, down $9.61 (-11.91%) from the previous close of $80.67. The session traded on 1.6× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $71.06 and $89.41, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Arrowhead Pharmaceuticals, Inc. (ARWR)
The consensus analyst price target on Arrowhead Pharmaceuticals, Inc. (ARWR) is $104.43, 47.0% above the recent $71.06. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ARWR line up.
The bullish case
- Wall Street's consensus price target of $104.43 implies +47.0% upside from $71.06.
- The Street's most bullish target is $126.00 (+77.3%).
- Arrowhead Pharmaceuticals, Inc. (ARWR) moved +4.01% from $71.65 to $74.52 on 2026-07-21.
The bearish case
- The most bearish analyst target is $46.00 (-35.3%).
- Material negative event.
- Sharp 11.9% decline — elevated risk.
- ARWR fell 3.18% to $80.22, primarily driven by profit-taking and consolidation following a strong multi-week rally, according to the web catalyst.
- Arrowhead Pharmaceuticals (ARWR) declined 4.17% to $81.37, driven by profit-taking in high-momentum biotech stocks following recent clinical updates and strong prior gains, combined with cautious sector sentiment in mid-cap biotechnology (per web synthesis).
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 15, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ARWR
In-depth ARWR event analyses
Frequently asked questions about ARWR
Why did Arrowhead Pharmaceuticals, Inc. (ARWR) stock move?
ARWR tumbled 11.9% to $71.06. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did ARWR stock fall?
ARWR lost 11.91% ($9.61) versus the prior close of $80.67, last trading at $71.06 on 1.6× average volume.
When is Arrowhead Pharmaceuticals, Inc.'s next earnings date?
ARWR's next earnings report is estimated for 2026-11-24 — about 70 days away.
What is the analyst price target for ARWR?
The consensus analyst price target for ARWR is $104.43, about 47.0% above the current $71.06. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.
How BestStocks tracks ARWR
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ARWR-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for ARWR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 15, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.